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Identification of atopic dermatitis subgroups in
children from 2 longitudinal birth cohortsLavinia Paternoster, PhD,a Olga E. M. Savenije, MD, PhD,b,c Jon Heron, PhD,d David M. Evans, PhD,a,e
Judith M. Vonk, PhD,c,f Bert Brunekreef, PhD,g,h Alet H. Wijga, PhD,i A. John Henderson, MD,d
Gerard H. Koppelman, MD, PhD,b,c* and Sara J. Brown, MD, FRCPEj,k* Bristol and Dundee, United Kingdom; Groningen,
Utrecht, and Bilthoven, The Netherlands; and Brisbane, AustraliaBackground: Atopic dermatitis (AD) is a prevalent disease with
variable natural history. Longitudinal birth cohort studies
provide an opportunity to define subgroups on the basis of
disease trajectories, which may represent different genetic and
environmental pathomechanisms.
Objectives: We sought to investigate the existence of distinct
longitudinal phenotypes of AD and test whether these findings
are reproducible in 2 independent cohorts.
Methods: The presence of AD was examined in 2 birth cohort
studies including 9894 children from the United Kingdom
(ALSPAC) and 3652 from the Netherlands (PIAMA). AD was
defined by parental report of a typical itchy and/or flexural
rash. Longitudinal latent class analysis was used to investigate
patterns of AD from birth to the age of 11 to 16 years. We
investigated associations with known AD risk factors, including
FLG null mutations, 23 other established AD-genetic risk
variants, and atopic comorbidity.
Results: Six latent classes were identified, representing
subphenotypes of AD, with remarkable consistency between the
2 cohorts. The most prevalent class was early-onset-early-
resolving AD, which was associated with male sex. Two classes
of persistent disease were identified (early-onset-persistent and
early-onset-late-resolving); these were most strongly associated
with the AD-genetic risk score as well as personal and parental
history of atopic disease. A yet unrecognized class of mid-onset-
resolving AD, not associated with FLG mutations, but strongly
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In clinical practice, atopic dermatitis (AD; eczema) demon-
strates a characteristic itchy erythematous rash1 but it has a
heterogeneous presentation with variations in timing of onset,
persistence,2,3 distribution, severity, association with allergic
sensitization,4 and comorbidity with other atopic diseases.5,6
Although the classification of eczema cases into atopic and
nonatopic forms is commonplace (in part because the underlying
etiology of these may be different4), the heterogeneity of
longitudinal disease course in AD is less well studied. Most AD
cases are diagnosed in early childhood and although most
resolve during childhood, some persist into adulthood. We
hypothesized that divergent temporal disease patterns may be
caused by different genetic and environmental etiological
mechanisms. Understanding these differences could influence
how AD is defined and treated, paving the way for a phenotype-
driven, more personalized approach to the management of
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2 PATERNOSTER ET ALAbbreviations usedAD: Atopic dermatitisALPSAC: Avon Longitudinal Study of Parents and ChildrenFLG: Gene encoding filaggrinLLCA: Longitudinal latent class analysisOR: Odds ratioPIAMA: Prevention and Incidence of Asthma and Mite AllergyAD is a strongly heritable condition. A total of 31 risk loci have
been identified in genetic association studies, including 24 loci
that were discovered in white European populations.7-13 The car-
dinal feature of an itchy erythematous rash is central to all case
definitions for AD, but large genetic studies have used a broad
case definition, including self-reported AD over a wide age range
of pediatric and adult patients. This broad case definition has been
necessary to allow collection of the large number of cases
required for genomewide analyses, but it does not allow for
detailed substratification of AD and dictates that such studies
are powered to detect variants common across subtypes of dis-
ease, while potentially missing variants with more specific effects
on subtypes of the disease.
The aim of our study was to investigate the existence of
longitudinal subphenotypes of AD and to test whether these
findings are reproducible in 2 independent birth cohorts. We used
longitudinal latent class analysis (LLCA), a statistical technique
that can be used to model potential subgroups within a data set, to
identify different longitudinal patterns of disease. We applied
LLCA to cohorts from the United Kingdom and the Netherlands
from birth to 16 years or 11 years, respectively. We tested each
latent class for association with known genetic and nongenetic
risk factors for AD and atopic comorbidities, to investigate the
existence of distinct subgroups of disease having different
etiological and prognostic profiles.METHODS
Avon Longitudinal Study of Parents and Children
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a
longitudinal population-based birth cohort study of 14,701 children from Avon,
United Kingdom. The study protocol has been described previously14 and
further details are in this article’s Online Repository at www.jacionline.org.
Information regarding the presence/absence of rash consistent withADwas
extracted from questionnaires completed by the mothers when the children
were aged between 6 months and 16.5 years (at 6, 18, 30, 42, 57, 69, 81, 103,
128, 140, 166, and 198 months). At each time point AD was defined as a
positive response to 1 of the following questions: ‘‘Has your child had an itchy,
dry, oozing or crusted rash on the face, forearms or shins?’’ (at age 6 months);
‘‘Has your child had a skin rash in the joints and creases of their body (e.g.
behind the knees, elbows, under the arms) in the past 6-12 months?’’ (18-
166 months); ‘‘Has your child had an itchy rash which was coming and going
for at least 6 months in the past 12 months and confined to the creases of the
knees/ankles/elbows or wrists?’’ (at 16 years).
Nongenetic risk factors were selected on the basis of existing evidence for
association with AD15 and data availability in the 2 cohorts. Parental history of
AD and asthma was parent-reported in questionnaires completed by the parents
or guardians. Breast-feeding was coded as a binary variable of never versus any
breast-feeding as reported by the mother when the child was 15months old. Cat
exposurewas coded as a binary variable of 0 or 11 cats in the home, as reported
by the mother at 8 weeks’ gestation. Children were classified as asthmatic at 7
and 13 years if a parent answered ‘‘yes’’ to ‘‘Has your child had asthma in the
past 12 months?’’ Total IgE level was measured in venous blood at 7 years
and total IgE level of more than 75 kU/L was defined as elevated.DNAwas obtained from blood and genotypes were determined according
to methods described in this article’s Online Repository at www.jacionline.
org. Individuals were categorized into 2 groups: those with and those without
any of the 4 gene encoding filaggrin (FLG) null mutations tested (ie, FLG2/2
and FLG1/2 vs FLG1/1).16 Genotypes for the remaining 23 established (and
replicated) European AD risk variants13 were combined into a score, with the
value representing a sum of the risk alleles carried across the 23 variants.Prevention and Incidence of Asthma and Mite
Allergy
Prevention and Incidence of Asthma andMite Allergy (PIAMA) is a Dutch
multicenter birth cohort of 3963 children from allergic and nonallergic
mothers. The study protocol has been described previously17 and further de-
tails are in this article’s Online Repository at www.jacionline.org.
The International Study of Asthma and Allergies in Childhood–based
questionnaires were used to report symptoms ofAD between age 3months and
11 years (3, 12, 24, 36, 48, 60, 72, 84, 96, 132months). At each time point, AD
was defined as a positive response to both of the following 2 questions: ‘‘Has
your child had an itching rash that was variably present in the last 12months?’’
(or ever at 3 and 12 months) and ‘‘Was this rash present around the eyes/ears,
foreside ankles, inner side knees or inner side elbows?’’ (also neck at 3 and
12 months).
Parental history of asthma was taken from questionnaires that asked ‘‘Have
you ever had asthma?’’ Any versus never breast-feeding was assessed by
questions on infant feeding in the questionnaires administered at age 3 months
and 1 year. Cat exposure was coded as a binary variable of 0 or 11 cats in the
home at 3 months after birth. Asthma at 7 and 11 years was defined as a
parental report of a doctor’s diagnosis of asthma at any time and a parental
report of asthma in the last 12months at age 7 and 11 years. Total IgE level was
measured in venous blood at age 8 years and a level of more than 75 kU/L was
defined as elevated.
DNA was obtained from blood and mouth swabs and genotypes were
determined according tomethods described in this article’s Online Repository.
FLG genotype categorization and the non-FLG genetic risk score were con-
structed, as for ALSPAC.
Statistical analysis
LLCAwas used to investigate heterogeneity in patterns of AD. As the name
suggests, this method is applied in longitudinal settings,18,19 where the aim is to
identify distinct subgroups in longitudinal multivariate categorical data. This is
akin to cluster analysis, but is more appropriate for binary data and allows for
assignment based on probability, rather than definitive partitioning of individ-
uals into classes. Starting with a single latent class, additional classes are added
until measures that estimate model fit are optimized. Several statistical criteria
(including low Bayesian information criterion, Vuong-Lo-Mendell-Rubin like-
lihood ratio test, and entropy) were assessed to determine the optimal number of
classes; full details are given in this article’s Online Repository at www.
jacionline.org. Model fitting was carried out in Mplus version 7.0.20
Model fit was primarily assessed using only those individuals for whom
there was no missing AD symptom data. However, to optimize the use of
available data and maximize the cohort size, results were compared with
analyses that included individuals for whom data were available for 50% or
more of the time points studied (>_6 of the 12 time points in the ALSPAC cohort
and >_5 of the 10 time points in the PIAMA cohort). Association analyses
primarily focused on this larger (although incomplete) data set, but results
were compared with models from the smaller but more complete data set.
Associations of risk factors and comorbidities with the latent classes were
tested using a manual implementation of the bias-adjusted 3-step analysis.21
This method accounts for uncertainty in class assignment (see this article’s
Online Repository at www.jacionline.org). Associations with established
risk factors (sex, family history of atopy, breast-feeding, presence of pet cat
in the household, FLG loss-of function mutation, genetic risk score of 23 es-
tablished white European AD variants) were tested using multinomial regres-
sion, whereas atopic comorbidities (asthma at ages 7 and 11 or 13 years;
elevated IgE level at age 7 or 8 years) were tested using logistic regression.
FIG 1. Prevalence and frequency of AD in UK and Dutch longitudinal
cohorts. Plot of frequency (right-hand axis) of AD cases (gray bars) and
controls (white bars) and AD prevalence (black points and left-hand axis)
over 12 time points in ALSPAC and 10 time points in PIAMA. AD is defined
by the presence of typical rash.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
PATERNOSTER ET AL 3RESULTS
LLCA in the ALSPAC cohort
The prevalence of AD in the ALSPAC cohort declined over
time (Fig 1, A) from 27% in the first year of life to 7% at age
16.5 years. Data were available from all 12 time points for a total
of 3480 individuals. The 6-class model was considered the best fit
to the data (as defined by the lowest Bayesian information crite-
rion); however, only small improvements were seen between
the 4-class and the 6-class models (see Table E1 and Fig E1 in
this article’s Online Repository at www.jacionline.org). We pre-
sent the results of the 6-class model as the primary analysis, but
show the results for the simpler 4-class model in this article’s On-
line Repository at www.jacionline.org, which for most analyses
produced very similar results.
A total of 9894 individuals had data available from at least 6 of
the 12 time points and the model fit parameters were broadly
consistent with the smaller but more complete data set (Table E1).
Comparison of models from the larger incomplete and smaller but
complete data sets showed that the prevalence patterns of AD by
class were very similar (see Table E3 in this article’s Online Re-
pository at www.jacionline.org) and only 3% of children (116 of
3480) changed best-fit class between the 6-class models in each
analysis (see Table E2 in this article’s Online Repository at
www.jacionline.org).
Fig 2,A, shows the estimated prevalence of a rash characteristic
of AD at each time point across the 6 classes in the analysis of
9894 individuals. Descriptions of the classes alongside the labels
we gave each class are given in Table I.
The estimated prevalence of a rash characteristic of AD at each
time point for the 4-class model is displayed in Fig E3 in this ar-
ticle’s Online Repository at www.jacionline.org. The 4 classes
can be described as follows: unaffected individual or transient
AD (61.9%); early-onset-persistent AD (10.7%); early-onset
AD resolving by age 11 years (16.5%); later-onset AD after age
3.5 years (10.9%). These 4 classes show substantial overlap
with the 6-class assignment (see Table E4 in this article’s Online
Repository at www.jacionline.org).LLCA in the PIAMA cohort
The prevalence of AD in the PIAMA cohort declined only
slightly from 18% in the first year of life to 14% by age 11 years
(Fig 1, B). Data were available from all 10 time points for 2063
individuals. A total of 3652 individuals had data available from
at least 5 of these time points, and we present the results from
the analysis of this larger incomplete data set. LLCA model fit
was similar to ALSPAC, with lowest Bayesian information
criteria achieved between the 4-class and 6-class models (see
Table E5 and Fig E2 in this article’s Online Repository at www.
jacionline.org), the resulting class patterns following a remark-
ably similar pattern to ALSPAC (Fig 2, B; see Fig E4 in this arti-
cle’s Online Repository at www.jacionline.org), with comparable
class prevalences (Table I and Fig 1, B).
As for ALSPAC, we present association results for the 6-class
model as the primary analysis because this showed best fit.
Comparison of assignment between 4- and 6-class models is
shown in Table E7 in this article’s Online Repository at www.
jacionline.org and association results from the 4-class model
are also shown in this article’s Online Repository.Associations between latent classes with family
history and selected environmental risk factors
The associations of 6 classes with potential AD risk factors are
summarized in Table II. The results from the smaller but complete
data set and the 4-class models are presented in Tables E9 and E10
in this article’s Online Repository at www.jacionline.org. Similar
conclusions could be drawn from these models, unless otherwise
specified.
In ALSPAC, taking the ‘‘unaffected or transient AD’’ class as
the baseline category, being female was a risk factor for the early-
onset-persistent, mid-onset, and late-onset classes, the strongest
association being with the late-onset class (odds ratio [OR], 1.90;
95% CI, 1.48-2.44; P5 43 1027). However, male sex was a risk
factor for the early-onset-early-resolving class (OR, 1.33; 95%
CI, 1.10-1.61; P 5 .004). A similar pattern was observed in
PIAMA, where the strongest association with female sex was
observed with the late-onset group (OR, 1.87; 95% CI, 1.21-
2.90; P5 .005) and there was evidence of an association between
male sex and early-onset-early-resolving class.
Maternal history of AD was associated with all classes in
ALSPAC,with the strongest association in the persistent class (OR,
3.16; 95%CI, 2.60-3.83; P5 43 10231). A similar pattern (albeit
with weaker evidence for all classes) was observed in ALSPAC for
maternal history of asthma, where again the strongest association
was with the persistent class (OR, 1.54; 95% CI, 1.22-1.95;
P5 33 1024). Paternal history of asthma showed a similar asso-
ciationwith this class (OR, 1.59), but the smaller sample sizemeant
there was less evidence for this result (P5 .139). Paternal asthma
also showed association with the early-onset-late-resolving class
(OR, 2.53; 95% CI, 1.30-4.91; P 5 .006). In PIAMA the
associations with maternal and paternal history of asthma
were similar, with strong associations with the persistent and
FIG 2. Longitudinal classes identified using LLCA in 2 independent birth cohorts: A, ALSPAC (n5 9894) and
B, PIAMA (n 5 3652).
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95% CI, 1.11-3.40, P 5 .021, and OR, 3.14, 95% CI, 1.76-5.61,
P 5 1 3 1024, respectively) and with the persistent group for
paternal history (OR, 2.69; 95% CI, 1.66-4.36; P5 63 1025).
In ALSPAC, breast-feeding was associated with a higher risk of
persistent and early-onset-late-resolving AD (OR, 1.42, 95% CI,
1.11-1.81, P5 .006, and OR, 1.53, 95% CI, 1.12-2.08, P5 .008,
respectively). There was little evidence of association with mid-
or late-onset classes. In PIAMA, there was little evidence for
breast-feeding being associated with any class.
Early-life exposure to a pet cat was not associated with any of
the latent classes in the primary analyses for ALSPAC or PIAMA.
However, this was the only risk factor in which a difference was
seen in the complete-case results in ALSPAC, where there was
some evidence of a protective effect of early-life cat exposure on
the early-onset-early-resolving class only (OR, 0.64; 95% CI,
0.46-0.90; P5 .010; Table E9). The same direction of effect was
observed in PIAMA but with a weaker and less precise estimate
(OR, 0.72; 95% CI, 0.50-1.04; P 5 .081).Associations between latent classes and atopic
traits and comorbidities
The associations of AD classes with elevated total IgE and
asthma are displayed in Table III. Raised IgE level was associatedwith the AD classes showing prevalent disease at the time of
testing, that is, age 7 to 8 years (the persistent, early-onset-late-
resolving, and mid-onset classes in ALSPAC and the persistent
class in PIAMA).
In ALSPAC, all classes showed association with asthma at age 7
and 13years. The associationswere strongest for the persistent class
(7 years: OR, 5.50, P 5 5 3 10241; 13 years: OR, 7.19;
P 5 3 3 10246) in which 29% reported asthma at age 7 years
(compared with 8% of the normal/transiently affected class),
increasing to 31% at 13 years (compared with 7% of the normal/
transient class). The early-onset-early-resolving class showed the
smallest increased risk of asthma at age 7 and 13 years (ORs, 1.56
and 1.79, respectively). In PIAMA, the persistent and early-onset-
late-resolving group showed association with asthma at age 7 years
(persistent OR, 14.27; P5 53 10215). At age 11 years, all but the
mid-onset-resolving group were associated, again the strongest as-
sociation being with the persistent group (OR, 15.35;
P5 33 10211).Associations between latent classes and genetic
risk variants
In ALSPAC, all classes other than the mid-onset class
showed association with FLG null mutations (Table IV). The
strongest association was for the persistent group (OR, 4.31;
TABLE I. Descriptions and prevalences of the classes in 2 independent cohorts
Class Description of class in ALSPAC ALSPAC prevalence PIAMA prevalence
Unaffected individuals or transient AD 64% of this class never had reported rash, others had 1 or 2
isolated occasions of rash; ;10% reported rash consistent
with AD at 6-18 mo and this declined with age
58.0% 62.9%
Early-onset-persistent AD At age 30 mo, ;85% of this class had reported rash, increasing
to >90% prevalence until 12 y; it then steadily declined to
;50% at 16.5 y
7.3% 4.9%
Early-onset-late-resolving AD In this class the prevalence of rash rose steeply to >95% at
30 mo and then steadily declined to ;10% by 16.5 y
7.0% 3.8%
Early-onset-early-resolving AD ;60% of children in this class had reported rash at 18 and
30 mo; this declined to 10% by 6-7 y
12.9% 15.4%
Mid-onset-resolving AD In this class there was a 10%-20% prevalence of rash until
30 mo, steeply rising to 75% prevalence at 5-6 y, and steadily
declining to <10% prevalence by 16.5 y
7.0% 6.5%
Late-onset-resolving AD In this class, ;30% reported rash at 18 mo, declining to ;10%
prevalence at 5-6 y, steadily rising to ;70% prevalence by
12 y and finally declining to 10% by 16.5 y
7.9% 6.5%
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PATERNOSTER ET AL 595% CI, 3.29-5.63; P5 23 10226); the other associated classes
had ORs of about half this (2.14-2.30). In PIAMA, only the
early-onset-late-resolving class was associated with FLG null
mutations (OR, 5.63; 95% CI, 2.65-11.95; P 5 7 3 1026);
however, the approximate number of FLG2/1 or FLG2/2
individuals in the PIAMA analyses was very low (between 7
and 14 individuals per class), so power was limited to identify
associations.
The combined genetic risk score encompassing all other AD
variants was associated with all but the early-onset-early-
resolving and the late-onset classes in the 6-class model in
ALSPAC. The association was strongest with the persistent class
(OR, 1.17; 95% CI, 1.12-1.22, for each additional risk allele;
P5 23 10213). A similar pattern was observed in PIAMA, with
the persistent class showing the strongest association and an
almost identical effect size to that seen in ALSPAC (OR, 1.17;
95% CI, 1.07-1.28; P 5 5 3 1024).
The associations for individual AD risk single nucleotide
polymorphism are presented in Table E11 in this article’s
Online Repository at www.jacionline.org. These analyses are
not well powered and should be interpreted with caution, but
some patterns are noteworthy. Most variants had the strongest
effects in the persistent class and 3 variants showed consistent
associations in ALSPAC and PIAMA: These were rs17881320
in STAT3, rs479844 near OVOL1, and rs6010620 in RTEL1.
One variant (rs1057258) showed evidence in ALSPAC for
association in the opposite direction to that reported previously
for AD with the late-onset and early-onset-early-resolving
classes (OR, 0.73, 95% CI, 0.57-0.93, P 5 .011, and OR,
0.80, 95% CI, 0.65-0.99, P 5 .039, respectively).
A consistent direction of effect (though with weak statistical
evidence) was observed for the late-onset class and this single
nucleotide polymorphism in PIAMA (OR, 0.74; 95% CI,
0.45-1.20; P 5 .218).DISCUSSION
Our results provide novel insights into the heterogeneity of AD
in childhood. We report 6 latent classes, representing subpheno-
types of AD with remarkable consistency between 2 independent
cohorts. The most prevalent class was early-onset-early-resolvingAD (13%-15%), which was associated with male sex. This class
has a favorable prognosis and is only very weakly associated with
asthma in later life. Two classes of persistent disease were
identified (early-onset-persistent and early-onset-late-resolving);
theseweremost strongly associatedwith anAD-genetic risk score
as well as personal and parental history of atopic disease.
Importantly, these classes display strong comorbidity with
asthma. A yet unrecognized class of mid-onset-resolving AD,
not associated with FLG mutations, but strongly associated with
asthma, was described. In this class, AD prevalence increases
sharply from age 2.5 years peaking at approximately 6 years.
The etiological factors in this class remain unclear because the
subgroup was not strongly associated with many of the known
risk factors, but does show strong association with asthma
comorbidity.
The clinical application of this LLCA is based on the clear
demonstration of distinct classes of AD phenotype with different
disease trajectories. The substantial diversity of disease that is
defined as ‘‘AD’’ (or ‘‘eczema’’) has long been recognized, and
clearer subdivisions are an essential prerequisite for the develop-
ment of stratified medicine approaches that will be needed for the
optimal application of novel biological therapies in the more
severe subgroups of AD. Therefore, further studies are needed to
define the most appropriate combinations of biomarkers and risk
factors to detect these subgroups prospectively and at an early
age.
There was some evidence of differential strength and presence
of associations with risk factors and comorbidities between the
classes. The early-onset-persistent class showed the strongest
associations (compared with other classes) with most well-
established risk factors and markers of severe atopic phenotype,
including FLG null mutations and a genetic risk score of other
AD-associated variants, coexistent asthma, and elevated IgE
and parental history of atopic disease. The associations with
asthma at ages 7 and 11 and 13 years were strongest with the
persistent class, but all AD classes showed evidence of some
increased risk of asthma at these ages. Our data did not support
the presence of a specific trajectory from AD to asthma (the so-
called atopic march), which is in keeping with a previous report
from the Manchester Asthma and Allergy Study (MAAS) and
earlier analyses in ALSPAC.6 The associations observed with
TABLE II. Association results between risk factors and AD classes identified by LLCA
Trait
Exposed/
Total Wald P Early-onset persistent
Early-onset late-
resolving
Early-onset early-
resolving
Mid-onset
resolving
Late-onset
resolving
ALSPAC 7.3% 7.0% 12.9% 7.0% 7.9%
Female 4805/9875 6 3 10217 1.56 (1.29-1.89)
P 5 6 3 1026
0.97 (0.77-1.22)
P 5 .811
0.75 (0.62-0.91)
P 5 .004
1.79 (1.40-2.29)
P 5 4 3 1026
1.90 (1.48-2.44)
P 5 4 3 1027
Maternal eczema 3154/9722 3 3 10243 3.16 (2.60-3.83)
P 5 4 3 10231
1.68 (1.32-2.14)
P 5 2 3 1025
2.00 (1.65-2.44)
P 5 4 3 10212
1.66 (1.29-2.13)
P 5 8 3 1025
1.75 (1.36-2.25)
P 5 1 3 1025
Maternal asthma 1554/9721 2 3 1024 1.54 (1.22-1.95)
P 5 3 3 1024
1.43 (1.08-1.91)
P 5 .014
1.23 (0.95-1.58)
P 5 .112
1.10 (0.79-1.53)
P 5 .566
1.02 (0.73-1.44)
P 5 .891
Paternal asthma 245/1568 .030 1.59 (0.86-2.93)
P 5 .139
2.53 (1.30-4.91)
P 5 .006
1.58 (0.86-2.89)
P 5 .139
0.94 (0.38-2.33)
P 5 .893
1.72 (0.83-3.57)
P 5 .146
Breast-feeding 7019/9198 9 3 1024 1.42 (1.11-1.81)
P 5 .006
1.53 (1.12-2.08)
P 5 .008
1.22 (0.97-1.54)
P 5 .093
1.04 (0.78-1.37)
P 5 .803
1.04 (0.78-1.38)
P 5 .800
Pet cat 2963/9511 .179 0.88 (0.71-1.09)
P 5 .226
1.14 (0.89-1.45)
P 5 .291
0.92 (0.74-1.13)
P 5 .427
0.81 (0.61-1.06)
P 5 .125
1.26 (0.98-1.62)
P 5 .073
PIAMA 4.9% 3.8% 15.4% 6.5% 6.5%
Female 1759/3652 .025 1.06 (0.75-1.49)
P 5 .743
0.63 (0.40-1.00)
P 5 .051
0.89 (0.64-1.24)
P 5 .494
0.94 (0.65-1.37)
P 5 .753
1.87 (1.21-2.90)
P 5 .005
Maternal asthma 259/3645 .001 1.94 (1.11-3.40)
P 5 .021
3.14 (1.76-5.61)
P 5 1 3 1024
1.33 (0.70-2.51)
P 5 .385
0.96 (0.41-2.24)
P 5 .932
1.38 (0.65-2.93)
P 5 .406
Paternal asthma 272/3633 .002 2.69 (1.66-4.36)
P 5 6 3 1025
0.91 (0.34-2.46)
P 5 .854
1.19 (0.63-2.25)
P 5 .585
1.72 (0.94-3.14)
P 5 .076
1.17 (0.53-2.61)
P 5 .697
Breast-feeding 2984/3614 .888 1.00 (0.63-1.56)
P 5 .983
1.34 (0.70-2.57)
P 5 .377
1.19 (0.75-1.89)
P 5 .461
0.97 (0.60-1.56)
P 5 .886
0.88 (0.52-1.48)
P 5 .634
Pet cat 1213/3651 .151 0.73 (0.50-1.06)
P 5 .098
0.80 (0.50-1.29)
P 5 .367
0.72 (0.50-1.04)
P 5 .081
1.0 (0.68-1.47)
P 5 .996
0.67 (0.42-1.07)
P 5 .094
‘‘Wald P’’ is for the overall omnibus test. Individual P values and effect sizes (OR and 95% CI) comparing each class with the ‘‘unaffected/transient’’ class are also shown; results
P < .05 are shown in boldface.
TABLE III. Association results between AD classes identified by LLCA and comorbidities
Trait Cases/Total Wald P
Early-onset
persistent
Early-onset
late-resolving
Early-onset
early-resolving
Mid-onset
resolving
Late-onset
resolving
ALSPAC 7.3% 7.0% 15.4% 7.0% 7.9%
Asthma at age 7 y 904/7859 2 3 10250 5.50 (4.28-7.05)
P 5 5 3 10241
3.08 (2.22-4.27)
P 5 2 3 10211
1.56 (1.09-2.24)
P 5 .015
2.23 (1.53-3.26)
P 5 3 3 1025
1.89 (1.26-2.83)
P 5 .002
Asthma at age 13 y 784/6752 7 3 10258 7.19 (5.48-9.42)
P 5 3 3 10246
3.59 (2.51-5.12)
P 5 2 3 10212
1.79 (1.20-2.65)
P 5 .004
3.41 (2.35-4.96)
P 5 1 3 10210
2.01 (1.30-3.12)
P 5 .002
Elevated IgE
level at age 7 y
2057/4790 8 3 10216 2.62 (1.98-3.47)
P 5 1 3 10211
1.92 (1.38-2.68)
P 5 1 3 1024
1.15 (0.88-1.51)
P 5 .310
1.55 (1.10-2.18)
P 5 .013
1.38 (0.99-1.93)
P 5 .059
PIAMA 4.9% 3.8% 15.4% 6.5% 6.5%
Asthma at age 7 y 94/3349 2 3 10215 14.27 (7.33-27.78)
P 5 5 3 10215
5.92 (2.31-15.16)
P 5 2 3 1024
3.03 (1.08-8.47)
P 5 .035
0.60 (0.03-13.62)
P 5 .750
1.73 (0.38-7.88)
P 5 .478
Asthma at age 11 y 102/2639 7 3 10211 15.35 (6.86-34.35)
P 5 3 3 10211
9.12 (3.49-23.82)
P 5 6 3 1026
4.91 (1.66-14.55)
P 5 .004
2.10 (0.42-10.53)
P 5 .366
5.70 (1.98-16.43)
P 5 .001
Elevated IgE
level at age 8 y
723/1707 1 3 1024 3.00 (1.85-4.86)
P 5 8 3 1026
1.58 (0.86-2.89)
P 5 .140
1.57 (0.97-2.56)
P 5 .067
1.42 (0.83-2.46)
P 5 .203
0.97 (0.53-1.77)
P 5 .914
‘‘Wald P’’ is for the overall omnibus test. Individual P values and effect sizes (OR and 95% CI) comparing each class with the ‘‘unaffected/transient’’ class are also shown; elevated
IgE level is defined as total IgE level of >75 kU/L; results P < .05 are shown in boldface.
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persistent disease, in keeping with previous reports.22 Within
the class of early-onset disease that resolved before the time of
IgE measurement, a smaller proportion of individuals had IgE
levels above the threshold defined as ‘‘elevated,’’ in comparison
with the class of early-onset disease that was still active. Further
investigation with earlier IgE measures is required to explore
whether such individuals would have had raised IgE level at the
time of active disease.Although being female was more strongly associated with the
early-onset persistent and late-onset classes, there was some
evidence that being male was differentially associated with early-
onset-resolving classes. It is tempting to speculate that the late-
onset class might represent AD induced by behavioral changes in
the adolescent child (including increased bathing/showering and
the use of fragranced products), which might differ between
males and females, but this hypothesis remains to be tested. The
male preponderance in AD cases ascertained in infancy has
TABLE IV. Association results between genetic risk factors and AD classes identified by LLCA
Study and genetic risk
factor
No. with risk
genotype/total Wald P
Early-onset
persistent
Early-onset late-
resolving
Early-onset early-
resolving
Mid-onset
resolving
Late-onset
resolving
ALSPAC 7.3% 7.0% 12.9% 7.0% 7.9%
FLG null mutation 813 of 7570 4 3 10228 131 of 570 (23%)* 78 of 514 (15%)* 111 of 832 (13%)* 54 of 467 (12%)* 70 of 499 (14%)*
4.31 (3.29-5.63)
P 5 2 3 10226
2.23 (1.53-3.26)
P 5 3 3 1025
2.14 (1.54-2.98)
P 5 7 3 1026
1.48 (0.92-2.39)
P 5 .109
2.30 (1.57-3.38)
P 5 2 3 1025
Genetic risk score
(all other
variants)
Total N 5 6497 8 3 10217 1.17 (1.12-1.22)
P 5 2 3 10213
1.08 (1.04-1.13)
P 5 4 3 1024
1.02 (0.99-1.06)
P 5 .222
1.06 (1.00-1.12)
P 5 .042
1.01 (0.96-1.06)
P 5 .758
PIAMA 4.9% 3.8% 15.4% 6.5% 6.5%
FLG null mutation 117 of 1516 6 3 1024 7 of 74 (10%)* 14 of 60 (23%)* 11 of 159 (7%)* 7 of 96 (7%)* 10 of 95 (11%)*
1.34 (0.49-3.67)
P 5 .563
5.63 (2.65-11.95)
P 5 7 3 1026
0.87 (0.25-3.03)
P 5 .821
0.95 (0.26-3.45)
P 5 .942
1.87 (0.76-4.62)
P 5 .174
Genetic risk score
(all other
variants)
Total N 5 1964 6 3 1025 1.17 (1.07-1.28)
P 5 5 3 1024
1.0 (0.91-1.11)
P 5 .968
1.16 (1.08-1.25)
P 5 1 3 1024
1.11 (1.03-1.20)
P 5 .004
1.08 (0.98-1.18)
P 5 .111
‘‘Wald P’’ is for the overall omnibus test. Individual P values and effect sizes comparing each class with the ‘‘unaffected/transient’’ class are also shown; results P < .05 are shown in
boldface; genetic risk score is defined by the total number of risk alleles across the 23 AD-associated loci (other than FLG) identified by genome-wide association study meta-
analysis to date; OR represents the change in odds per risk allele for the genetic risk score or between carriers compared with noncarriers for the FLG mutations.
*To demonstrate the approximate numbers of individuals with FLG null mutations in each class, individuals were assigned to the most likely class. Given that the actual association
analysis accounted for uncertainty in assignment of classes, these values are approximations for purposes of highlighting where power might be low. The approximate number with
FLG null mutations/approximate total with FLG genotype data (%), within each class are shown. The ‘‘unaffected/transient’’ groups had 8% (;369 of 4712) and 7% (;68 of 1032)
with FLG mutations in ALSPAC and PIAMA, respectively.
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this sex difference are unknown.
There is conflicting epidemiological evidence indicating that
breast-feedingmay be either a risk factor or a protective factor in the
etiology of AD27 and our analyses have not been able to add clarity
to this important question. In the ALSPAC cohort, breast-feeding
was associated with the 2 classes of most long-lasting disease
(early-onset-persistent and early-onset-late-resolving AD) but in
the PIAMA cohort there was little evidence of breast-feeding being
associated with any of the latent classes. This apparent difference
could be explained in several different ways: It may be stochastic
(given that all 95% CIs overlap between the 2 cohorts); it may be
a result of the substantially higher prevalence of breast-feeding in
the Dutch population compared with the UK population; or it
may result from reverse causation in the ALSPAC cohort, if, for
example, mothers with a strong history of atopic disease are more
likely to breast-feed their infants.
We found little evidence for early-life exposure to a pet cat
being associated with any of the classes in the main analysis.
However, in the complete-case data set in ALSPAC, there was
some evidence that cat exposure may have a protective effect on
early-onset-early-resolving AD, which is somewhat at odds with
previous reports of cat exposure increasing the risk of AD.28,29
This may indicate a specific beneficial effect of early cat exposure
on this more transient phenotype and warrants further
investigation.
There was evidence that FLG null mutations were associated
with all classes; however, as reported previously,30,31 the associ-
ation was strongest in the group with early-onset-persistent dis-
ease. The genetic risk score of the other established AD
variants showed a similar pattern, whereby the association was
strongest for the early-onset-persistent class, with a striking in-
crease in the burden of risk of approximately 17% per additional
risk allele. Of note, 3 variants showed consistent patterns of ef-
fects across both cohorts, with stronger associations in theearly-onset persistent group, and weaker associations with the
other classes. The functional mechanisms of these loci have not
been fully defined, but rs17881320 is within STAT3 (encoding a
signal transducer and activator of transcription, an acute-phase
response protein); rs479844 is near to OVOL1 (which encodes
zinc-finger containing transcription factor); and rs6010620 is
within RTEL1 (regulator of telomere elongation helicase 1).
This heterogeneity of effect of genetic variants on different dis-
ease profiles emphasizes the need for patient stratification in
future genetic studies. Stratification may be used to increase the
power to detect variants associated with specific classes; stratifi-
cation could also allow the identification of phenotype-specific
mechanistic pathways as future therapeutic targets.
The similarity and high frequency of AD symptom ascertain-
ment in ALSPAC and PIAMA are strengths of our study. The
phenotype definitions used within the cohorts comprised pro-
spective questions to capture diagnostic features of eczema
including the changing distribution of skin involvement from
infancy to later childhood. One key difference is that PIAMA had
a shorter follow-up (11 years vs 16 years), which could have
limited the ability to detect classes with differences at later ages.
Despite this, the class patterns are remarkably similar between
ALSPAC and PIAMA (Fig 2). However, neither cohort allowed
for investigation of variable AD patterns in adulthood, more sub-
tle AD patterns (such as the transient cases that were indistin-
guishable from the unaffected individuals in our study), nor in
people of ancestries other than white European. We also studied
only a limited number of environmental factors and so this
work could be extended to investigate the association between
latent classes and other potential risk factors.
Although individuals are not assigned to classes with complete
certainty (see Table E8 in this article’s Online Repository at www.
jacionline.org), the LLCA 3-step method models this uncertainty
and allows for the inclusion of individuals with incomplete data
to maximize sample size and minimize any loss to follow-up
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rection and some risk factors studied do not entirely precede the
onset of disease. Therefore, although the observational associations
are interesting, furtherwork shouldbe conducted to investigate cau-
sality. A further challenge is that by stratifyingAD into smaller sub-
phenotypes of disease,we inevitably lower the power of association
testing. Few studies have such detailed longitudinal data and so to
increase sample sizes in future studies, it will be necessary to
extrapolate these data-driven phenotypes into settings where less
detailed data are available, such as large data registries.32
In conclusion, we have identified longitudinal subgroups of AD
that have both shared and distinctly different risk factor profiles.
Future studies of the etiology and treatment of this complex trait
should take these subgroups of disease into account and, in turn,
this may offer valuable stratified medicine approaches to refining
prognostic predictions and therapeutic strategies.
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Clinical implications: AD ranges from a transient condition to
lifelong morbidity. This study has identified distinct subpheno-
types of AD in children, which could indicate the importance of
a stratified approach to the management of this complex
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